PUNE, India, April 4, 2017 /PRNewswire/ --
ReportsnReports.com adds "Thalassemia - Pipeline Review, H1 2017" to itsstore providing comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers
Browse 33 market data tables and 11 figures; spread across 140 pages is available at http://www.reportsnreports.com/reports/928826-thalassemia-pipeline-review-h1-2017.html
Companies discussed in this Thalassemia Pipeline Review, H1 2017 report include Acceleron Pharma Inc, Agios Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, bluebird bio Inc, Calimmune Inc, CRISPR Therapeutics, Editas Medicine Inc, Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc, Incyte Corp, Ionis Pharmaceuticals Inc, IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc, PharmaEssentia Corp, Protagonist Therapeutics Inc, Sangamo Therapeutics Inc and Zydus Cadila Healthcare Ltd.
Drug Profile mentioned in this research are ACY-957, AG-348, ALN-TMP, ambrisentan, ATIR-201, BB-305, benserazide, CAL-H, CNTO-530, CordIn, Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia, Gene Therapy for Sickle Cell Disease and Thalassemia, Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia, GSK-2696277, IMR-687, IONISTMPRSS-6LRx, LJPC-401, luspatercept, M-009, M-012, NiCord, PEG-EPO, PHBB-101, PTG-300, RCY-1497, RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia, ruxolitinib phosphate, SCD-101, sirolimus, Small Molecule for Beta Thalassemia and Sickle Cell Anemia, Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia, Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours, sotatercept, Stem Cell Therapy for Beta Thalassemia , Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease , Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease and Thalagen.
Order a Purchase Copy of this Report @ http://www.reportsnreports.com/purchase.aspx?name=917734
The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 6, 17 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Scope of this report: The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Infectious Disease). The pipeline guide reviews pipeline therapeutics for Thalassemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Thalassemia (Infectious Disease) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Thalassemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Infectious Disease).
This guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2017
Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2017
Burns - Pipeline Review, H1 2017
Explore more reports on Pharmaceuticals Market http://www.reportsnreports.com/market-research/pharmaceuticals/.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari 2nd Floor, Metropole Building Next to Inox Theatre Bund Garden Road Pune - 411013 Maharashtra, India +1-888-391-5441 email@example.com
Connect with Us:
LinkedIn: http://www.linkedin.com/company/reportsnreports RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Subscribe to our Free Newsletters!